Less than two years after pulling multiple myeloma therapy Blenrep off most markets around the world, GSK has filed for approval of the drug in the EU once again, hoping to restore its bloc
Sanofi has hit back on a decision by NICE not to recommend NHS use of Sarclisa as part of a regimen for relapsed and refractory multiple myeloma (RRMM), claiming the agency would not consid
The European Commission has approved Sobi’s long-acting factor VIII replacement therapy Altuvoct for the treatment of haemophilia A in the EU, with a broad label that spans all ages and any
There’s no doubt that CAR-T therapies have transformed the treatment of many blood cancers, but a risk of secondary malignancies has cast a pall over the class.
One of the lead candidates in Sanofi natural killer (NK) cell engager alliance with Innate Pharma has shown encouraging and durable efficacy in various haematological cancers, according to
AstraZeneca’s Calquence has been shown to improve progression-free survival in previously untreated mantle cell lymphoma (MCL), with an unprecedented trend towards improved overall survival
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh